Successful Treatment Without Using Dantrolene Sodium on a Child Occurring Malignant Hyperthermia During Induction of General Anesthesia: A Case Report.
Journal
The Journal of craniofacial surgery
ISSN: 1536-3732
Titre abrégé: J Craniofac Surg
Pays: United States
ID NLM: 9010410
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
received:
23
12
2023
accepted:
15
01
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
ppublish
Résumé
Malignant hyperthermia (MH) is a fatal hyperthermia with a high mortality, which usually occurs during induction of general anesthesia. Dantrolene sodium is a wonder drug currently used for treating malignant hyperthermia. However, preparing, storing, and maintaining dantrolene sodium are crucially expensive, thus making it financially unsatisfactory and difficult for clinicians to acquire in time. Monitoring patients' condition closely and intervening promptly when early signs of malignant hyperthermia occur can effectively prevent the condition from worsening and win over time for the arrival of dantraline sodium. This article is to report a case in which we successfully rescued a child occurring malignant hyperthermia without using dantrolene sodium.
Identifiants
pubmed: 38829149
doi: 10.1097/SCS.0000000000010077
pii: 00001665-202406000-00079
doi:
Substances chimiques
Dantrolene
F64QU97QCR
Muscle Relaxants, Central
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e351-e354Informations de copyright
Copyright © 2024 by Mutaz B. Habal, MD.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Rosenberg H, Sambuughin N, Riazi S, et al. Malignant hyperthermia susceptibility in. GeneReviews® [Internet]. University of Washington; 2003
Pinder RM, Brogden RN, Speight TM, et al. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1977;13:3–23
Shi Y, Wang Y, Wei H. Dantrolene : from malignant hyperthermia to Alzheimer’s disease. CNS Neurol Disord Drug Targets 2020;18:668–676
Ratto D, Joyner RW. Dantrolene, in StatPearls [Internet] . StatPearls Publishing; 2023
Hopkins PM, Gupta PK, Bilmen JG. Malignant hyperthermia. Handb Clin Neurol 2018;157:645–661
Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene—a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364–373
Ho PT, Carvalho B, Sun EC, et al. Cost-benefit analysis of maintaining a fully stocked malignant hyperthermia cart versus an initial dantrolene treatment dose for maternity units. Anesthesiology 2018;129:249–259
Kim HJ, Koh WU, Choi JM, et al. Malignant hyperthermia and dantrolene sodium. Korean J Anesthesiol 2019;72:78–79
Ndikontar R, Etoundi PO, Tochie JN, et al. Malignant hyperthermia, a rare perioperative complication: case series and literature review. Oxf Med Case Reports 2020;2020:omaa101
Pollock RA, Britt BA. Malignant hyperthermia in the head and neck surgery patient: an update and review. Laryngoscope 1983;93:318–325
Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020. Anaesthesia 2021;76:655–664
Rosenberg H, Pollock N, Schiemann A, et al. Malignant hyperthermia: a review. Orphanet J Rare Dis 2015;10:93
Schuster F, Johannsen S, Roewer N, et al. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag 2014;10:355–362